NEXT BIOMEDICAL completed an FDA pre-submission review for Nexsphere-F under the TAP program. NexEos Bio received IND clearance to begin a Phase II/III trial of NTX-1024 for vernal keratoconjunctivitis, supported by positive early clinical data.
Aldeyra Therapeutics announced CEO Dr. Todd Brady will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, in New York. The live webcast will be available on the company's website and archived for 90 days. Aldeyra is a biotechnology company focused on therapies for immune-mediated diseases.
The FDA cleared NexEos Bio's IND application to proceed with a Phase II/III trial of NTX-1024 ophthalmic solution for vernal keratoconjunctivitis, following positive results from a 15-patient study in Mexico.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07675811 |
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy |
RECRUITING | PHASE3 |
| NCT07309432 |
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy |
RECRUITING | PHASE3 |
